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Human IFN-/32 cytokine produced in E. cofi was purified to homogeneity by immunoaffinity and ion-exchange chromatog- 
raphy. The cytokine inhibits the growth of myeloleukemic Ml cells and induces their morphological and functional diffe- 
rentiation into macrophages. Differentiation was also observed in the histiocytic lymphoma U937 cells. The effect on 
U937 was synergized by IFN-y and under these conditions IFN-82 produced the induction of (2’-5’) oligo(A) synthetase 
typical to IFN action and to differentiation. 
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1. INTRODUCTION 
Leukemic cells proliferate without limit and 
without undergoing normal hematopoietic ter- 
minal differentiation, often having lost their re- 
quirements for exogenous growth factors or 
colony-stimulating factors (CSFs), presumably 
because of epigenetic alterations imposed by 
overexpression of oncogenes [l-3]. An important 
feature of this epigenetic defect is that it can be 
reversible, several chemical agents being able to 
push the cells toward differentiation and concomi- 
tant growth arrest [3,4]. Moreover, a number of 
naturally occurring cell-secreted protein factors 
(cytokines), produced physiologically in the 
organism, have now been found to restore the dif- 
ferentiation and growth arrest of leukemic cell 
lines in vitro, suggesting that these proteins may 
have antitumor regulatory functions in vivo [3,4]. 
For example, myeloid differentiation is induced in 
murine myeloleukemic ells such as WEHI-3B D+ 
and Ml by hematopoietic olony-stimulating fac- 
tors, e.g. G-CSF [5-71, and by other factors 
devoid of growth-stimulatory activity such as 
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MGI-2 [4,8] and LIF [9]. Among the im- 
munoregulatory cytokines, tumor necrosis factor 
(TNF-cr) was found to induce differentiation of 
human myeloblastic ML-l cells [lo]. Interleukin-1 
(IL-la) acts in synergism with TNF-cy or interferon 
(IFN-,&) to induce monocytic differentiation of the 
Ml cells [ll]. Since both TNF and IL-l are strong 
inducers of the cytokine IFN-@/IL-6 [IFN-&2 [ 131 
is also referred to as B-cell stimulatory factor 2 
(BSF-2), hybridoma plasmacytoma growth factor 
(HGF), hepatocyte stimulatory factor, 26 kDa 
protein and interleukin 6 (IL-6)] [12,13] and since 
this cytokine inhibits growth of carcinoma, lym- 
phoma and leukemia cells [ 14,151, we investigated 
its effect on the differentiation of Ml cells. We 
show here that recombinant, E. co/i-produced, 
unglycosylated IFN-,82 induces mass cultures of 
Ml myeloblasts to differentiate into growth- 
arrested macrophage-like cells, and causes partial 
differentiation of human histiocytic lymphoma 
U937 cells. 
2. MATERIALS AND METHODS 
Human recombinant IFN-&? was purified from E. co/i 
JMlOl i“ harboring the direct expression plasmid pkk@2/7 
[IS], which was grown to an ~~~~~ value of 30 in a 16 1 
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Microgen Fermentor SF-116 (New Brunswick Sci., NJ), 
harvested and disrupted by glass beads in a Dyno-Mill type 
KDL as detailed [16]. The extract was freed of nucleic acids by 
polyethyleneimine precipitation [16] and passage through 
DEAE-cellulose in 25 mM Tris-HCl (pH 7.5), 25 mM NaCl. 
Purification was achieved by chromatography on sulfonyl (S)- 
Sepharose (Pharmacia, NJ) in 10 mM Na acetate buffer (pH 
5.0) with a O-O.3 M NaCl gradient, followed by fast protein 
liquid chromatography (FPLC) on Mono-S (Pharmacia) under 
the same conditions. Whereas mammalian cell-produced IFN- 
,&2 has 23 and 26 kDa forms [13], the E. co/i preparation 
showed a single band at 21 kDa by SDS-polyacrylamide gel 
electrophoresis (fig.]). The first amino acid was identified as 
ProZ9 of the IFN-&2, sequence [13]. Measured by stimulation of 
[3H]thymidine incorporation in plasmacytoma Tl165 cells (Dr 
R. Nordan, NIH) the specific activity was 2 x lo6 U/mg 
(BSF-2/HGF activity). An alternative purification based on im- 
munoaffinity chromatography was carried out as in [16] with 
immobilized anti-IFN-fl monoclonal antibodies (hybridoma 
clone 34), the protein being eluted by citrate buffer (pH 2) and 
immediately neutralized. The specific activity of the im- 
munopurified recombinant protein was the same as that ob- 
tained by chemical purification. The IFN-,02 preparation 
titrating 350000 U/ml contained an amount of lipolysaccharide 
of 6 pg/ml as measured by the limulus test. Human recombi- 
nant IFN-y (10’ U/mg) was obtained from hamster cells as 
described [17]. 
Costar plates. Pure rlFN-fl was added at 0.1-75 ng/ml and 
the cultures were observed for 4-6 days. Cells were counted and 
stained for Giemsa and for non-specific esterase using the LY- 
naphthyl acetate esterase kit 91-A of Sigma (St. Louis, MO). 
Lysozyme activity was measured in 0.5% Triton X-100 cell ex- 
tracts by a turbimetric assay of the lysis of Micrococcus 
lysodeikticus (Sigma), the assay being calibrated with egg-white 
lysozyme as described 181. The (2’-S’)oligo(A) synthetase ac- 
tivity was assayed in Nonidet-P40 cell extracts as described [20]. 
3. RESULTS 
Murine myeloleukemic Ml cells [18] and human lymphoma 
U937 cells [19] were grown in RPM1 1640 with 10% fetal calf 
serum (FCS). The cells were seeded at 105/ml in wells of 12-well 
S-Seph Mono-S 
- ,67 
45 - 
- 
- 
Without addition, the Ml cells grew without 
adhering to the dish and showed typical 
myeloblastic morphology. In contrast, after 4 days 
of culture with IFN-,82, the cells were adherent and 
showed dramatic morphological changes (fig.2). 
About 60% of the cells acquired macrophage-like 
morphology, the rest showing various degrees of 
maturation. Cytoplasms were enlarged, contained 
vacuoles and acquired a typical foamy appearance. 
Nuclei were eccentric, less round and contrasted, 
and had less prominent nucleoli. Viable cell count- 
ing showed that while the control culture grew for 
6 days, the Ml cells treated with 50 U/ml IFN-,02 
underwent 2-3 divisions and growth was arrested 
(table 1). At day 4 after seeding, less than 1 U/ml 
IFN-fi2 (expressed in plasmacytoma growth units, 
see section 2) was sufficient to cause a 50% 
decrease in Ml cell number (fig.3). The growth- 
arrest effect was maximal above 30 U/ml IFN-,82 
(15 ng/ml). Even with the chemically purified 
rIFN-@2, this concentration corresponds to no 
more than 2.5 pg/ml LPS which had no effect on 
the Ml cells. Growth inhibition and differentiation 
of Ml cells were observed when IFN-,82 was added 
with 5 pg/ml polymyxin B, further excluding any 
role of LPS traces. As a biochemical marker of dif- 
ferentiation we measured lysozyme activity [8] in 
extracts of 5 x lo6 Ml cells cultured for 4 days 
with 30 U/ml IFN-P;?. Lysosyme was undetectable 
in the control Ml cultures. Treatment with IFN-P;? 
induced lysozyme to levels of 0.85 pg lysozyme 
equivalent per 5 x lo6 cells. Phagocytic activity on 
latex beads was also observed in the differentiated 
Ml cells. Thus IFN-fl inhibits growth of Ml cells 
and induces their monocytic differentiation. 
Fig. 1. Polyacrylamide gel electrophoresis in SDS of rIFN-@2, 
after the sulfonyl-Sepharose step (2.4 pg, left lane) and after the 
Mono-S FPLC step (0.4pg, right lane). The middle slot 
contained sample buffer only. Silver stain. 
Human histiocytic lymphoma U937 cells can be 
induced to differentiate by phorbol esters and 
vitamin D3, and partially by IFN-7 and other yet 
unidentified cytokines 121,221. We examined the 
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Fig. 
in a 
.2. Morphological differentiation of Ml myeloblasts induced by rIFN-m/IL-6. The culture was initiated by seeding 10’ cells/ml 
12-well Costar plate in the absence (left) and presence of rIFN-fl (FPLC purified, 150 BSF U/ml). After 4 days cells were Giemsa 
stained. Representative fields are shown (magnification x 400). 
effect of 100 U/ml IFN-@2 addition on U937 
cultures. After 4-5 days, about 25% of the cells 
showed monocytic/macrophage morphology and 
there was a 30% reduction in cell growth (table 2). 
The cells were stained for a-naphthyl acetate 
esterase, as a biochemical marker of differentia- 
Table 1 
Effect of IFN-m/IL-6 on myeloleukemic Ml cell growth 
IFN-/32 
(BSF U/ml) 
Cell number (x lo-‘) 
Day 0 Day 1 Day 4 Day 5 Day 6 
0 1 2.3 19.0 25.0 35.0 
25 1 2.0 3.5 0.9 0.7 
50 1 1.4 2.3 0.8 1.2 
Recombinant E. coli IFN-&? purified by Mono-S FPLC 
1.4 
Yi 1.3~ .z 1.2 - 
E ‘;‘- 
t 0.9- 
J3 
E 
O.B- 
2 0.7 - 
0.8 . 
F OS- 
u 0.4. 
0.3 - 
0.2 
0 0.25 1.2 6 30 150 
rlFN -BZ(E.cdi) Mono-S FPLC, BSF U/ml 
Fig.3. Growth inhibition of Ml myeloblasts by rIFN-@/IL-6. 
Same experiment as in fig. 1 with various concentrations of the 
cytokine. 
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Table 2 
Effect of IFN-m/IL-6 on histiocytic lymphoma U937 cell 
growth and differentiation 
Expt IFN+‘2 Cell number Esterase-positive 
(BSF U/ml) (x 10-s) cells (070) 
1 0 14.0 (100) 4 
100 10.0 (71) 24 
2 0 26.7 (100) ND 
150 23.5 (88) ND 
1500 14.5 (54) ND 
Cells treated for 5 days with or without rIFN-fl2 purified on 
Mono-S FPLC. Staining for non-specific esterase as in section 2 
tion not induced by IFN-y [22]. About one quarter 
of the cells in the IFN-m-treated culture were 
strongly positive for the non-specific esterase, 
whereas few positive cells were observed in the un- 
treated (table 2) or mock-treated culture (not 
shown). With higher amounts of the pure rIFN-,K? 
preparations, growth inhibition (table 2) and par- 
tial morphological changes, such as cytoplasmic 
enlargement and nucleus indentation, were more 
pronounced. However, we found that when added 
together with IFN-7, the effect of low-dose IFN-P;! 
was significantly potentiated (table 3). Under these 
conditions, cell growth was reduced and most of 
the cells showed cytoplasmic enlargement, changes 
in nuclear shape and nucleolus reduction, although 
monocytic differentiation was still incomplete. We 
previously reported that early during differentia- 
tion of U937 cells in response to phorbol esters, 
there was a marked rise in (2’-5’)-A synthetase ac- 
tivity of the cells [23]. Induction of (2’ -5 ‘)-A syn- 
thetase is mediated by an autocrine IFN and was 
Table 3 
Synergistic effects of IFN-m/IL-6 and IFN-7 on histiocytic 
lymphoma U937 cells 
IFN-fl 
(BSF U/ml) 
IFN-y Cell number (2’-5 ‘)A synthetase 
(U/ml) (x 10-q activity 
( [32P]A2 ’ pA cpm) 
0 0 20 (100) 110 
15 0 14 (70) 310 
0 100 12 (60) 940 
15 100 8.5 (42) 4000 
Cells treated for 6 days with or without rIFN-/32 
immunoaffinity purified 
302 
related to the growth arrest associated with ter- 
minal differentiation [20,22,23]. The addition of 
IFN-7 strongly potentiated the induction of 
(2’ -5 ‘)-A synthetase by IFN-P;! (table 3), sug- 
gesting that the two cytokines cooperate to initiate 
the differentiation process, although other addi- 
tions may be required to observe complete dif- 
ferentiation of the type seen with the Ml cells. 
4. DISCUSSION 
Induction of terminal differentiation in 
myelomonocytic leukemic cell lines is a novel addi- 
tional activity of the multifunctional cytokine IFN- 
p2/IL-6. This protein, first identified and cloned 
from human diploid fibroblasts induced by viruses 
or poly(rI)(rC) to produce IFN-fl activities [24,25], 
was later found to be identical to B-cell stimulatory 
factor 2 (BSF-2 or IL-6) produced by an 
HTLVl-transformed T cell clone [26]. This IL-6 
activity enhances immunoglobulin secretion in 
mature B lymphocytes and the lymphoblastoid cell 
line CESS, and may contribute to the differentia- 
tion of plasma cells. The cytokine has growth fac- 
tor activity for Epstein-Barr virus-transformed 
human B lymphocytes [27] and for several 
plasmacytomas and hybridomas [28]. Activation 
of T-cell functions was also reported [29]. Another 
important activity is expressed in hepatocytes 
where IFN-,K! activates the expression of a battery 
of genes encoding the acute phase proteins, such as 
fibrinogen, antiproteases and components of the 
complement system [30]. The cytokine also induces 
complement factor B and C3 synthesis in 
fibroblasts, which may provide a local activation 
of the alternative complement pathway during in- 
fections [3 11. 
The different activities found associated with 
IFN-P2/IL-6 suggest hat this cytokine plays im- 
portant functions in the defense against infections 
and in inflammatory processes [14,311. The pro- 
tein is induced in various cells by viruses, by 
bacterial products such as LPS [3 1,321 as well as by 
the inflammatory cytokines TNF and IL-l 
[ 12,13,3 11. Monocytes produce IFN-/32 either 
spontaneously or after stimulation by phytohem- 
agglutinin [33]. A role in infections/inflammation 
is further supported by the fact that IFN-P;! 
stimulates hematopoiesis and more specifically 
myelopoiesis, a process characteristic of inflamma- 
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tions. Thus, in bone marrow and blood cultures in 
vitro, IFN-fl2 synergizes the effect of multipoietin 
IL-3 on formation of blast colonies [34] and of dif- 
ferentiating hematopoietic colonies of the 
myelomonocytic, erythroid and mixed lineages 
[35]. IFN-P;? does not work as a colony-stimulating 
factor (CSF) by itself but stimulates hematopoietic 
progenitor cells in liquid cultures to respond to 
CSF and form colonies when plated on agar [35]. 
The differentiation of myeloblastic leukemic cells 
described here may, therefore, reflect the effect on 
normal hematopoiesis, rather than just overcom- 
ing the differentiation block due to the leukemic 
state. 
During terminal differentiation, leukemic as 
well as normal cells undergo growth-arrest in 
Go/G1 and down-regulation of proto-oncogene ex- 
pression [20]. This is accompanied by production 
of an autocrine interferon activity usually of the /3- 
type, as attested by the increase in (2 ’ -5 ‘) oligo(A) 
synthetase and blockage with anti-IFN-fi an- 
tibodies [20,22,23]. In the U937 cells, phorbol 
esters induce IFN-,&2 RNA [36] although other 
studies suggest an RNA related to IFN-fil is made 
[20]. Here we show that IFN-fl2 induces the typical 
(2’-5 ‘) oligo(A) synthetase increase in U937 par- 
ticularly in synergism with IFN-y, conditions 
which enhance differentiation. The Ml cells re- 
spond to lung-conditioned medium [20] as well as 
to TNF and IL-l [l l] by production of IFN activi- 
ty and increase in (2’-5’) oligo(A) synthetase. 
Neutralization of this IFN activity prevents the 
growth arrest [ 11,20,22]. Mouse IFN#i did not in- 
duce Ml cell differentiation alone [ll]. The pre- 
sent evidence that IFN-P;! inhibits Ml cell growth 
and causes their differentiation suggests that IFN- 
,&2 could play this autocrine IFN function in cell 
differentiation. Recent results indicate that the dif- 
ferentiation factor MGI-2 [4,8] is identical to 
murine IL-6 (Sachs, L., personal communication). 
MGI-2 is made as an autocrine factor in response 
to several CSFs [4] and we have observed that IFN- 
p2 RNA is induced in bone marrow cells treated 
for 15 days with GM-CSF (Stephen, M. and Revel, 
M., unpublished). Although natural IFN-,f32 is a 
complex glycoprotein [37], the unglycosylated 
recombinant protein used in this work appears 
very active as a growth inhibitor and differentia- 
tion factor. Whether IFN-,&2/IL-6 acts directly to 
induce growth arrest and differentiation or induces 
still other cellular factors is not yet clear. However, 
some direct effect would be in line with the growth- 
inhibitory action of IFN-fi2 on a number of cell 
lines [15]. 
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